Publications

Detailed Information

Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy

DC Field Value Language
dc.contributor.authorLee, Se-Hoon-
dc.contributor.authorBang, Yung-Jue-
dc.contributor.authorMainwaring, Paul-
dc.contributor.authorNg, Christina-
dc.contributor.authorChang, John W-C-
dc.contributor.authorKwong, Philip-
dc.contributor.authorLi, Rubi K.-
dc.contributor.authorSriuranpong, Virote-
dc.contributor.authorToh, Chee-Keong-
dc.contributor.authorYuan, Jinyu-
dc.contributor.authorPitman Lowenthal, Susan-
dc.contributor.authorChung, Hyun C.-
dc.date.accessioned2021-01-31T11:01:39Z-
dc.date.available2021-01-31T11:01:39Z-
dc.date.created2020-12-17-
dc.date.issued2014-09-
dc.identifier.citationAsia-Pacific Journal of Clinical Oncology, Vol.10 No.3, pp.237-245-
dc.identifier.issn1743-7555-
dc.identifier.other119269-
dc.identifier.urihttps://hdl.handle.net/10371/172974-
dc.description.abstractAims: We evaluated and compared the safety and efficacy of sunitinib in Asian and non-Asian patients with metastatic renal cell carcinoma enrolled in a previously reported global expanded access program. Methods: Previously treated and treatment-naive patients received open-label sunitinib at a starting dose of 50 mg/day for 4 weeks, followed by 2 weeks off treatment, in repeated 6-week cycles. Safety was assessed regularly, tumor measurements were performed per local practice, and survival data collected where possible. Results: Data were available for 212 Asian patients from Asian sites (Asian-A), 113 Asian patients from non-Asian sites (Asian-O) and 4046 non-Asian patients. The most common grade 3/4 treatment-related adverse events were neutropenia, thrombocytopenia, hand-foot syndrome, diarrhea, asthenia and fatigue. The incidence of many adverse events was greater in Asian-A than in Asian-O or non-Asian patients. Sunitinib efficacy was comparable between Asian and non-Asian patients, with an objective response rate of 18% versus 14%; median progression-free survival of 8.7 versus 10.9 months; and overall survival of 18.9 versus 18.4 months, respectively. Conclusions: Sunitinib demonstrated tolerable safety and similar efficacy in Asian and non-Asian patients. Geographic differences in the reported frequency of specific adverse events were noted across Asian patients.-
dc.language영어-
dc.publisherBlackwell Pub. Asia-
dc.titleSunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy-
dc.typeArticle-
dc.contributor.AlternativeAuthor방영주-
dc.identifier.doi10.1111/ajco.12163-
dc.citation.journaltitleAsia-Pacific Journal of Clinical Oncology-
dc.identifier.wosid000340544000006-
dc.identifier.scopusid2-s2.0-84906242695-
dc.citation.endpage245-
dc.citation.number3-
dc.citation.startpage237-
dc.citation.volume10-
dc.identifier.sci000340544000006-
dc.description.isOpenAccessN-
dc.contributor.affiliatedAuthorBang, Yung-Jue-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.subject.keywordPlusENDOTHELIAL GROWTH-FACTOR-
dc.subject.keywordPlusTYROSINE KINASE INHIBITOR-
dc.subject.keywordPlusINTERFERON-ALPHA-
dc.subject.keywordPlusJAPANESE PATIENTS-
dc.subject.keywordPlusPHASE-II-
dc.subject.keywordPlusIN-VIVO-
dc.subject.keywordPlusSU11248-
dc.subject.keywordPlusTOXICITY-
dc.subject.keywordPlusSURVIVAL-
dc.subject.keywordPlusCANCER-
dc.subject.keywordAuthorAsian-
dc.subject.keywordAuthormetastatic renal cell carcinoma-
dc.subject.keywordAuthorsunitinib-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share